Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis-Reference-Cited by-同舟云学术

Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis

Published:2021-10-01 Issue:10 Volume:157 Page:1237
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Nguyen Michelle Nadeau¹,Reyes Melissa¹,Jones S. Christopher¹

Affiliation:

1. Division of Pharmacovigilance, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2784044/jamadermatology_nguyen_2021_ld_210019_1634154579.90868.pdf

Reference6 articles.

1. Epidemiology of locally advanced or metastatic urothelial cancer in the US, Europe, and Japan.;Bharmal;Value Health,2017

2. Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson syndrome/toxic epidermal necrolysis to dermal hypersensitivity reaction.;Viscuse;Front Oncol,2021

3. A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis.;Francis;JAAD Case Rep,2020

4. National Comprehensive Cancer Network – Guidelines for Bladder Cancer. Accessed February 2, 2021. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

5. The Human Protein Atlas (2015). Tissue expression of NECTIN-4. Accessed October 21, 2020. https://www.proteinatlas.org/ENSG00000143217-NECTIN4/tissue

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

2. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database;Frontiers in Immunology;2024-08-20

3. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

4. Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma;Japanese Journal of Clinical Oncology;2024-07-30

5. Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review;Journal of the American Academy of Dermatology;2024-06